 CELEBRATION, Fla., Dec. 22, 2020 GLOBE NEWSWIRE -- KemPharm, Inc. OTCQB: KMPH, a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it has filed an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA to begin human clinical trials of KP879. KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder SUD. 